SC vs. IV administration of a BCMA-CD3 bispecific antibody for R/R myeloma VJHemOnc – Video Journal of Hematology & HemOnc 3:30 3 years ago 128 Скачать Далее
Phase I trial of a BCMA-CD3 bispecific antibody in R/R myeloma VJHemOnc – Video Journal of Hematology & HemOnc 3:20 3 years ago 147 Скачать Далее
Efficacy and safety of elranatamab BCMA-CD3 bispecific antibody, in patients with RRMM International Myeloma Foundation 7:06 3 years ago 1 069 Скачать Далее
Bispecific BCMA-CD3 antibody teclistamab is efficacious and tolerable in R/R MM VJHemOnc – Video Journal of Hematology & HemOnc 1:29 3 years ago 86 Скачать Далее
Exciting results for BCMA/CD3 bispecific elranatamab (PF-3135) in R/R MM VJHemOnc – Video Journal of Hematology & HemOnc 3:34 4 years ago 679 Скачать Далее
Phase I study of ABBV-383, a BCMA×CD3 bispecific antibody, in R/R myeloma VJHemOnc – Video Journal of Hematology & HemOnc 1:14 1 year ago 107 Скачать Далее
REGN5459, a BCMA×CD3 bispecific antibody, in R/R multiple myeloma VJHemOnc – Video Journal of Hematology & HemOnc 5:28 1 year ago 162 Скачать Далее
Teclistamab, a BCMA × Cd3 Bispecific Antibody, in Pts with RRMM: Updated Phase 1 Results International Myeloma Foundation 9:57 3 years ago 1 122 Скачать Далее
Updated phase 1 results of teclistamab, a BCMA × CD3 bispecific antibody, in RRMM International Myeloma Foundation 7:25 3 years ago 395 Скачать Далее
Evaluating Teclistamab in Relapsed and/or Refractory Multiple Myeloma International Myeloma Foundation 8:12 3 years ago 699 Скачать Далее
First-in-human study of talquetamab: a GPRC5D-CD3 bispecific antibody for R/R MM VJHemOnc – Video Journal of Hematology & HemOnc 2:25 3 years ago 167 Скачать Далее
Alnuctamab, a BCMA x CD3 T-Cell Engager, in Pts with Relapsed/Refractory Multiple Myeloma International Myeloma Foundation 8:36 1 year ago 547 Скачать Далее
The importance of BCMA-targeting ADCs and bispecific antibodies in R/R multiple myeloma VJHemOnc – Video Journal of Hematology & HemOnc 3:28 1 year ago 126 Скачать Далее
Targeting BCMA with bispecific antibodies in R/R myeloma VJHemOnc – Video Journal of Hematology & HemOnc 1:23 5 years ago 116 Скачать Далее
First-in-Human Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Pts w/RRMM International Myeloma Foundation 4:28 2 years ago 248 Скачать Далее
Updated IV and SC Results from a Phase I Dose Escalation Study of Forimtamig with RRMM Patients International Myeloma Foundation 12:17 1 year ago 329 Скачать Далее
Clinical activity and safety of cevostamab in relapsed/refractory multiple myeloma International Myeloma Foundation 6:27 3 years ago 541 Скачать Далее
COLUMBA: subcutaneous daratumumab vs. IV administration VJHemOnc – Video Journal of Hematology & HemOnc 4:59 5 years ago 1 170 Скачать Далее
Phase 3 study of SC vs IV daratumumab in patients with relapsed or refractory multiple myeloma International Myeloma Foundation 5:20 5 years ago 304 Скачать Далее
Talquetamab: GPRC5D-CD3 bispecific antibody in R/R myeloma VJHemOnc – Video Journal of Hematology & HemOnc 4:15 3 years ago 548 Скачать Далее
